ClinicalTrials.gg
CompletedNCT04018248Updated Sep 10, 2025

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

A Phase 1 interventional study of BR101801 (Phase Ia) and BR101801 (Phase Ib) in Diffuse Large B Cell Lymphoma, Follicular Lymphoma and Chronic Lymphocytic Leukemia, sponsored by Boryung Pharmaceutical Co., Ltd. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 97 studies in Lymphoma, Large B-Cell, Diffuse with a site in Korea, Republic of — 15 open to participants now, 34 under way, 11 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Korea, Republic of.

Enrollment
73rd of 87
26 · median 90
Started
2020
with 4 others
Phase 1
15 of 97
1 open now
Registered
55th of 97
by date

Among the 97 studies in Lymphoma, Large B-Cell, Diffuse with a site in Korea, Republic of, this one is the 73rd largest by enrollment of the 87 interventional ones that give a count, is one of 5 that started in 2020, is one of 15 in phase 1, and was the 55th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

15 of the 97 studies in Lymphoma, Large B-Cell, Diffuse with a site in Korea, Republic of are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Lymphoma, Large B-Cell, Diffuse with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib).

The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RP2D) of BR101801 in subjects with relapsed/refractory B cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), and peripheral T cell lymphoma (PTCL).

The Phase Ib (dose expansion) part of the study is designed to assess tumor response and safety in specific advanced relapsed/refractory Peripheral T-cell lymphoma(PTCL) at a dose of BR101801 identified in Phase Ia. Once the RP2D has been determined in Phase Ia (dose escalation), Phase Ib (dose expansion) will commence.

Read the detailed description
  1. Phase Ia (Dose Escalation)

    Primary Objectives

    • To assess the safety and tolerability of BR101801 in patients with relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL.
    • To assess DLT and to determine the MTD and/or the RDE dose for BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression.

    SecondaryObjectives

    • To characterize the plasma and urine PK of BR101801.
    • To assess the preliminary antitumor activity of BR101801.
  2. Phase Ib (Dose Expansion)

Primary Objectives

  • To assess the safety and tolerability of BR101801 at the RP2D dose in subjects with relapsed/refractory Peripheral T-cell lymphoma (PTCL).

SecondaryObjectives

  • To assess clinical activity of BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression.
  • To assess the plasma PK of BR101801.

OUTLINE: This is a Phase I, multi-center, open-label, FIH study. The safety monitoring committee(SMC) will be responsible for safety oversight.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia
  • B Cell Lymphoma
  • Marginal Zone Lymphoma
  • Waldenstrom Macroglobulinemia
  • Peripheral T Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

\<Inclusion Criteria>

  1. Patients must sign an document
  2. Female or male patients aged ≥ 18 years.
  3. performance status ≤ 2.
  4. more than 3 months.
  5. Phase Ia:Patients with relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL diagnosed with World Health Organization (WHO) classification
  6. Phase Ib: Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL.
  7. Patients have based on the appropriate tumor type criteria( Phase Ib only)
  8. Have a current need for systemic therapy, the assessment of the investigator.
  9. An archival or fresh tumor tissue (ie, tissue block or series of at least 5 slides, up to 15 slides) is required and should be provided during the Screening Visit for Lymphoma subjects. Local review of pathology is required for study entry in Phase Ib only.
  10. Phase Ia subjects should be prepared to undergo a fresh tumor during the study (tumor biopsies will be obtained from 1 to 2 subjects per cohort in Phase Ia).
  11. Subject having laboratory values defined as:

    • (measured or calculated per institutional standard practice) ≥ 60 mL/min. can also be used in place of creatinine clearance.
    • Total \< 1.5 × , except for subjects with Gilbert's syndrome who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin \< 1.5 × ULN.
    • \< 2.5 × ULN, except for subjects who have tumor involvement of the liver, who are included if ALT \< 5 × ULN.
    • AST \< 2.5 × ULN, except for subjects that have tumor involvement of the liver, who are included if AST \< 5 × ULN.
    • > 1.0 × 109/L.
    • count > 75 × 109/L.
    • > 8 g/dL.

\<Exclusion Criteria>

  1. Presence of overt or active , or CNS metastases that require local CNS-directed therapy or increasing doses of within the prior 2 weeks. Patients with treated brain metastases should be neurologically stable and off steroids for at least 2 weeks before administration of any study treatment.
  2. Impaired cardiac function or cardiac disease
  3. Patients with interstitial pneumonia or history of drug-induced interstitial pneumonia/pneumonitis.
  4. (HIV) infection.
  5. Patients who are positive for surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or virus antibody (HCVAb).
  6. Chronic liver disease or chronic hepatitis
  7. Any gastrointestinal disorders interfering with study drug absorption or are unable to swallow tablets or capsules.
  8. Malignant disease, other than that being treated in this study.
  9. Prior PI3K inhibitor will be accepted in the dose escalation part of the study (Phase Ia) only.
  10. For patients with lymphoma:

    • Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon [INF], and toxin immunoconjugates) or any experimental therapy within 3 weeks or 5 half lives, whichever is shorter, before the first dose of study treatment.
    • Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment.
    • Unconjugated monoclonal antibody therapies \< 6 weeks before the first dose of study treatment.
  11. Patients receiving systemic chronic steroid therapy or any therapy (≥ 10 mg/day prednisone or equivalent).
  12. Use of any against infectious diseases within 4 weeks of initiation of study treatment.
  13. Use of hematopoietic colony-stimulating growth factors, thrombopoietin mimetics, or erythroid-stimulating agents ≤ 2 weeks prior to start of study drug.
  14. Patients with a history of stroke or having active neurological symptoms, with the exception of chronic conditions which, in the opinion of the neurologist, Investigator, and the Sponsor, would not impact ongoing neurologic assessments while on study treatment.
  15. Active infection requiring systemic or antiviral antibiotic therapy.
  16. Subjects with active CMV infection.
  17. Subjects receiving moderate or potent inhibitors or inducers and are unable to withdraw until 2 weeks or 5 times longer than the half-life, whichever is shorter, before the first dose of study treatment.
  18. Major surgery within 2 weeks of the first dose of study treatment (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery).
  19. Radiotherapy within 2 weeks of the first dose of study treatment, except for palliative radiotherapy to a limited-field, such as for the treatment of bone pain or a focally painful tumor mass.
  20. Presence of ≥ Grade 2 toxicity (except alopecia, peripheral neuropathy, and ototoxicity, which are excluded if ≥ CTCAE Grade 3) due to prior cancer therapy.
  21. Participation in an interventional, study within 2 weeks or 5 half-lives, whichever is shorter, of the first dose of study treatment.
  22. Any medical condition that would, in the Investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results.
  23. Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Treatment (BR101801): Phase Ia (dose escalation)

    Patients will receive BR101801 capsules orally, QD in 28-day cycles. The regimen may be changed to BID dosing based on emerging data.

    Drug: BR101801 (Phase Ia)

  • Experimental
    Treatment (BR101801):Phase Ib (dose expansion)

    • Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL

    Drug: BR101801 (Phase Ib)

Interventions

  • DrugBR101801 (Phase Ia)

    Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.

  • DrugBR101801 (Phase Ib)

    Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.

06

What researchers measure

Primary outcomes

  1. To determination of the MTD and RDE based on DLTs during Cycle 1 (Phase Ia)

    The recommended dose is determined by the number of patients who experience a dose limiting toxicity (DLT).

    Time frame: From baseline to Week 4

  2. Number of participants with adverse events (AE) as a measure of safety and tolerability of BR101801 when administered at the MTD or recommended dose (Phase Ia and Ib)

    To evaluate safety and tolerability the aggregate review will include but is not limited to: * CTCAE TEAEs, treatment-related TEAEs, Grade 3 or higher TEAEs, Grade 3 or higher treatment-related TEAEs, serious treatment-related TEAEs, and TEAEs leading to death. * Laboratory results; * Vital signs; * ECGs; * Physical examination * ECOG performance status

    Time frame: through study completion, and about average of 1 year

Secondary outcomes

  1. Cmax

    Maximum concentration obtained directly from the observed concentration versus time data.

    Time frame: Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15

  2. AUC(0-inf)

    Area under the plasma concentration-time curve from time zero extrapolated to infinity, calculated by linear up/log down trapezoidal summation

    Time frame: Cycle1( each cycle is 28 days) Day 1

  3. AUC(0-last)

    Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration

    Time frame: Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, Pre-dose to 24 hours after dosing

  4. AUC(0-tau)

    Area under the plasma concentration-time curve from time zero during a dosing interval

    Time frame: Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, dosing interval: 24 or 12 hours

  5. Ae

    Cumulative amount of unchanged drug excreted in urine

    Time frame: Cycle 1( each cycle is 28 days)Day 15, Pre-dose to 12 hours for BID dosing and Pre-dose to 24 hours for QD dosing

07

Study locations

9 sites
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • National Cancer Center
    Goyang-si, Gyeonggi-do, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do, South Korea
  • Chonnam National University Hwasun Hospital
    Hwasun, Jeollanam-do, South Korea
  • Inje University Busan Paik Hospital
    Busan, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul national university hospital
    Seoul, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Sep 2023, 41 months.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's 41 months is below that.

Counting every sponsor, half of 196 studies reached it within 55 months; a quarter within 36 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2019
First posted
Jul 12, 2019
StartActual
Apr 21, 2020
Primary completionActual
Sep 21, 2023
CompletionActual
Sep 21, 2023
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04018248
Responsible party
Sponsor
First posted
Jul 12, 2019
Start date
Apr 21, 2020
Primary completion
Sep 21, 2023
Completion
Sep 21, 2023
Last update
Sep 10, 2025

Study contacts

TM Kim, M.D, Ph.D
principal investigator · Seoul National University Hospital
SJ Kim, M.D, Ph.D
principal investigator · Samsung Medical Center
DH Yoon, M.D, Ph.D
principal investigator · Asan Medical Center
Jorge Chaves, M.D, Ph.D
principal investigator · Northwest Medical Specialities, PLLC
Emily Curran, M.D, Ph.D
principal investigator · University of Cincinnati
JS Kim, M.D, Ph.D
principal investigator · Severance Hospital, Yonsei University Health System
EY Lee, M.D, M.S
principal investigator · National Cancer Center
JO Lee, M.D, Ph.D
principal investigator · Seoul National University Bundang Hospital
DH Yang, M.D, Ph.D
principal investigator · Chonnam National University Hospital
WS Lee, M.D, Ph.D
principal investigator · Inje University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion